Xcout Intel
Smart Health Diagnostics Co
Smart Health Diagnostics Co. operates as a healthcare diagnostics holding company that oversees specialized portfolio businesses focused on pathology, oncology, and vascular diagnostics. The company provides slide-free digital pathology technology through its MUSE microscopy system and offers vascular diagnostic tools like SmartVascular Dx to detect vascular inflammation for clinicians and healthcare systems.
Subscribe to see Smart Health Diagnostics Co’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Smart Health Diagnostics Co at a glance
Smart Health Diagnostics Co is a healthcare diagnostics company headquartered in United States. Its most recent funding round raised $300,000 in November 2024. Xcout tracks 12 named people at Smart Health Diagnostics Co, including Larry Dentice (CEO & Director).
Smart Health Diagnostics Co leadership
- Larry DenticeCEO & Director
- Matthew NunezPresident & Director
- Mitch LevinePresident, Chief Financial Officer, and Director
- Gary FudgeChairman of the Board
- Lawrence DenticeExecutive Officer
- Matthew NunezExecutive Officer
6 more named people on record for Smart Health Diagnostics Co, with roles, board committees and tenure — see the full roster →
Smart Health Diagnostics Co funding rounds
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| SEC Form D filing | $300,000 | — | |
| SEC Form D filing | $1.3M | — | |
| Pre-Seed | $15.6M | — | |
| SEC Form D filing | $15.6M | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Smart Health Diagnostics Co competitors
A few of Smart Health Diagnostics Co's closest competitors — see the full list of competitors and alternatives →
Biocare Medical develops and supplies advanced staining instruments, primary antibodies, and detection reagents for immunohistochemistry (IHC), in situ hybridization (ISH), and fluorescence in situ hybridization (FISH). The company serves clinical laboratories, research facilities, and pathologists by providing integrated automated staining platforms and testing solutions.
Royal Biotech Inc. develops, manufactures, and markets portable diagnostic analysis products, handheld systems, and test kits for clinical, veterinary, food safety, and environmental applications. The company serves public security and health sectors by providing molecular and microfluidic diagnostic devices designed for on-site use.
TopoDx, Inc. develops physical AI technology for clinical microbiology to provide rapid microbial topographies for pathogen identification and antimicrobial susceptibility testing. The company serves hospitals and healthcare providers by delivering faster sample triage to enable quicker and more effective infection treatments.
CelLBxHealth plc is a medical diagnostics firm specializing in the creation of cancer detection solutions, with operations spanning the United Kingdom, broader Europe, North America, and other global markets. A flagship offering is the Parsortix PC1 system, a medical device engineered to isolate and collect whole circulating tumor cells (CTCs) from the blood of patients with metastatic breast cancer, preparing them for further user-validated analysis. The company also provides the Parsortix PR1 system for general CTC capture and collection from blood samples. Beyond its core systems, CelLBxHealth offers the Portrait+ CTC Staining kit, a laboratory solution designed for the precise identification, characterization, and quantification of both epithelial and mesenchymal circulating tumor cells, boasting strong analytical sensitivity and specificity. Another key product is the CellKeep Slide, which facilitates CTC harvesting. The company extends its expertise through various laboratory services, including advanced CTC enrichment and liquid biopsy analysis. Its assay portfolio comprises Portrait Flex, an immunofluorescence assay for detecting epithelial, mesenchymal, and epithelial-to-mesenchymal transition states, as well as assessing DNA damage response. Additionally, CelLBxHealth provides Portrait PD-L1 for CTC evaluation and develops customized CTC assays. Strategic collaborations underpin some of its development efforts; it has partnered with BioView Ltd to co-develop a human epidermal growth factor receptor 2 (HER2) assay kit for breast cancer, and an agreement with NuProbe USA, Inc. involves utilizing a pan-cancer next-generation sequencing (NGS) panel. Originally established in 1994 as ANGLE plc, the company rebranded to CelLBxHealth plc in October 2025 and operates from its base in Guildford, UK.
Get Smart Health Diagnostics Co's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Smart Health Diagnostics Co in Xcout Intel
- 12 named people with titles, LinkedIn and board committees
- 4 funding rounds with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access